Article

Lecanemab binds to transgenic mouse model-derived amyloid-β fibril structures resembling Alzheimer’s disease type-I, type-II and Arctic folds

2025-01-18

Abstract excerpt

Lecanemab, an Alzheimer’s disease US Food and Drug Administration approved monoclonal antibody was previously reported to have a high affinity against intermediately sized amyloid-β aggregates. Subsequently, it was observed by immunogold labelling that lecanemab can also bind to human type-I amyloid-β fibrils. Therefore, to determine whether lecanemab binds to amyloid-β fibril structures other than type-I, we perf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2f16399e-9e79-5f4a-95c3-fa80e6fa463f
DOI: 10.1101/2025.01.17.633637

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lecanemab binds to transgenic mouse model-derived amyloid-β fibril structures resembling Alzheimer’s disease type-I, type-II and Arctic foldsDOI 10.1101/2025.01.17.633637Read

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.Semantic proximity Read

Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesSemantic proximity Read

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brainSemantic proximity Read

Divergent age-dependent conformational rearrangement within Aβ amyloid deposits in APP23, APPPS1, and App <sup>NL-F</sup> miceSemantic proximity Read

Structure of Crenezumab Complex with Aβ Shows Loss of β-HairpinSemantic proximity Read

Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s diseaseSemantic proximity Read

Fatal Iatrogenic Cerebral Amyloid-Related Encephalitis in a patient treated with lecanemab for Alzheimer’s disease: neuroimaging and neuropathology.Semantic proximity Read

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencySemantic proximity Read

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialSemantic proximity Read

Fatal Iatrogenic Cerebral Amyloid-Related Encephalitis in a patient treated with lecanemab for Alzheimer’s disease: neuroimaging and neuropathologySemantic proximity Read

Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathologySemantic proximity Read

SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregationSemantic proximity Read